first conference at the EU level to discuss antibiotic resistance in humans and animals. The outcome of this conference is referred to as 'The Copenhagen Recommendations' that also encompassed the correlation of consumption with resistance [1] .
These recommendations paved the way to a number of EU funded projects on antimicrobial consumption, antimicrobial stewardship and antimicrobial resistance.
Less than ten years after 'The Copenhagen Recommendations' the EU issued an updated European Council (EC) Recommendation (2009/C 151/01 of 9 June 2009) on patient safety [2] . This included the prevention and control of Health Care Associated Infections (HAIs) specifically 'article II. 8 .c' i.e., to establish or, where already present, strengthen active surveillance at institution, regional and national level. This EC Recommendation was issued just months after a publication entitled 'Turning the tide of antimicrobial resistance: Europe shows the way' was published in Euro-surveillance, the ECDC scientific journal [3] . This publication stated that evidence from some European countries showed that it is possible to reverse the progress of antimicrobial resistance through prudent use of antibiotics, better adherence to infection control practices and immunisation.
Many EU presidencies focussed on antimicrobial resistance and these presidencies triggered many actions in the European Union. Some of the presidencies with the biggest impact were:
•Denmark (September- Many recommendations and concrete actions were proposed and agreed in four priority areas [4] . The European Commission agreed to fund research on: (i) the development of hand hygiene campaign materials tailored to the Member States, with the involvement of social marketing companies and behaviour scientists with evaluation of hand hygiene campaign materials; (ii) studying the effect on infection rates, either alone or in consort with other actions; and (iii) understanding human factors for compliance. The experts proposed that hospital CEOs should (i) be involved in hand hygiene campaigns; (ii) report on adherence to these campaigns in their hospitals; and (iii) be accountable for adverse events.
SURVEILLANCE

European antimicrobial resistance surveillance (EARSS)
The European Union (EU) took a stance on antimicrobial re- [6] .
Looking at EARS-Net data for MRSA for the past decade 
European surveillance of antimicrobial consumption (ESAC)
Surveillance of antimicrobial resistance cannot be a stand-alone initiative. Surveillance of antimicrobial consumption is an equally important factor in order to determine trends and possible quality indicators. The need for surveillance of antimicrobial consumption was recognised a year later than that of resistance [7] . The aim of ESAC was to collect comparable and reliable an-timicrobial consumption data across Europe [9] . Thus the Anatomic Therapeutic Chemical (ATC) classification and the Defined Daily Dose (DDD) were selected as numerator for national data sets whilst the denominator chosen was the number of inhabitants based on the mid-year population of the country.
Back then the DDD values for 2004 were used as these were current at the time of data collection. National antimicrobial consumption was therefore represented as DDD per 1000 inhabitants per day (DID) [10] .
The level of total AC antimicrobial use across Europe varied considerably [11, 12] . Indeed such differences were also observed for different drug classes, namely: antifungals [13] , fluoroquinolones [14] ; cephalosporins [15] ; penicillins [11] ; and 'macrolides, lincosamides, streptogramins and ketolides' (MLSK) [16] . Differences were also observed for the level of 'out-patient parenteral antibiotic treatment' (OPAT) [17] . However, the overall antimicrobial use in Europe is lower than the US average of 25 DID, with only 3 of 27 European countries showing higher use [18] . 
RESEARCH
Since 1999, the EU has spent EUR 800 Million on AMR Research. Two new research tools were developed:
Joint Programming Initiative (JPI)
The aim of Joint Programming Initiative is to pool national research efforts in order to make better use of Europe's public The objective of the agreement is to stimulate cooperation by bringing the best researchers together to exchange ideas and experiences, and to enhance their international profile and knowledge. The initiative will make it easier for early-career Korean top scientists to be part of ERC-funded research teams for six to twelve months.
ERC
Public Private Partnership (PPP): Innovative Medicines Initiative (IMI)
Unlike drugs used in the treatment of chronic non-communicable diseases, which do not become ineffective with usage, antibiotics do become ineffective within a few years of clinical use. This implies that antibiotic development is not as profitable so the Pharma-industry is deserting the anti-infective branch of R&D making the antibiotic pipeline drier [29] . From an industry point of view antibiotics are not as interesting because these cure and not control the condition so treatment is not prolonged.
Indeed, most antibiotics in most indications are used for 1-2 weeks only [30] . In recent decades the pharmaceutical industry has decreased the research and development (R&D) budget into antimicrobials as these are usually used on a short term basis and therefore the developers do not make enough turnover before the expiry of the patent [31, 32] . This could be partly attributable to the fact that commercially available antibiotics are cheap, broad spectrum effective and safe. Furthermore, antibiotics are used for a short period of time unlike chronic medication. We are currently using derivatives of the original drugs that were originally put in clinical use decades ago. (Fig. 1 ).
An important aim of ND4BB is also to develop a data repository that is sustainable beyond the life of the current programme, so that ND4BB will provide a key information base for research projects focused on antibiotic resistance. All consortia participating in topics running under the ND4BB research programme will be expected to deposit data in the ND4BB data hub and work together to share data and experience as widely as possible amongst all programme members and the antibiotic community as a whole.
Finally, ND4BB will establish a network of investigators that will exist beyond the life of these particular IMI calls. The biggest current challenge remains resistance among Gramnegative bacteria.
